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Abstract
Background: Nearly half of all mental health disorders develop prior to the age of 15. Early assessments, diagnosis,
and treatment are critical to shortening single episodes of care, reducing possible comorbidity and long-term
disability. In Norway, approximately 20% of all children and adolescents are experiencing mental health problems.
To address this, health officials in Norway have called for the integration of innovative approaches. A clinical
decision support system (CDSS) is an innovative, computer-based program that provides health professionals with
clinical decision support as they care for patients. CDSS use standardized clinical guidelines and big data to provide
guidance and recommendations to clinicians in real-time. IDDEAS (Individualised Digital DEcision Assist System) is a
CDSS for diagnosis and treatment of child and adolescent mental health disorders. The aim of IDDEAS is to
enhance quality, competency, and efficiency in child and adolescent mental health services (CAMHS).
Methods/design: IDDEAS is a mixed-methods innovation and research project, which consists of four stages: 1)
Assessment of Needs and Preparation of IDDEAS; 2) The Development of IDDEAS CDSS Model; 3) The Evaluation of
the IDDEAS CDSS; and, 4) Implementation & Dissemination. Both qualitative and quantitative methods will be used
for the evaluation of IDDEAS CDSS model. Child and adolescent psychologists and psychiatrists (n = 30) will
evaluate the IDDEAS` usability, acceptability and relevance for diagnosis and treatment of attention-deficit/
hyperactivity disorder.
Discussion: The IDDEAS CDSS model is the first guidelines and data-driven CDSS to improve efficiency of diagnosis
and treatment of child and adolescent mental health disorders in Norway. Ultimately, IDDEAS will help to improve
patient health outcomes and prevent long-term adverse outcomes by providing each patient with evidence-based,
customized clinical care.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: carolyn.clausen@ntnu.no
1Regional Center for Child and Youth Mental Health and Child Welfare
(RKBU)- Central Norway, IPH, Faculty of Medicine and Health Sciences, The
Norwegian University of Science and Technology (NTNU), Trondheim,
Norway
Full list of author information is available at the end of the article
Clausen et al. BMC Medical Informatics and Decision Making          (2020) 20:232 
https://doi.org/10.1186/s12911-020-01239-2
(Continued from previous page)
Trial registration: ISRCTN, ISRCTN12094788. Ongoing study, registered prospectively 8 April 2020 https://doi.org/10.
1186/ISRCTN12094788
Keywords: Child and adolescent mental health services (CAMHS), Clinical decision support system (CDSS),
Innovation, Attention-deficit/hyperactivity disorder (ADHD), IDDEAS, Norway
Background
Mental health disorders today account for more years
lived with disability (YLDs) than any other health condi-
tion, with close to 30% of all people worldwide having a
mental health disorder at one point during their life-
times [1, 2]. Children and adolescents are particularly
vulnerable. Nearly 20% of all children and adolescents at
any point in time have a diagnosable mental health dis-
order [3, 4]. Despite this, no more than one-third of all
children and adolescents with mental health disorders
worldwide receive the care they require [5].
In Norway, approximately 20% of all children and ado-
lescents are experiencing mental health problems at any
point in time [6, 7]. Both, academic pressure at school
and social pressure among peers, contribute to children
and adolescents reporting more stress now than ever be-
fore [8]. While primary care providers (PCPs) often serve
as the first point of contact for patients and their fam-
ilies, still most PCPs do not hold adequate training to
address complex neuropsychiatric disorders, such as aut-
ism spectrum disorder (ASD) and attention-deficit/
hyperactivity disorder (ADHD) [9–12].
Inability to receive a timely diagnosis and appropriate
early intervention for neuropsychiatric disorders in
childhood and adolescence leads to higher risk of suffer-
ing from comorbid mental health problems, including
alcohol and substance abuse, behavioral problems [9,
13]. Insufficient access to required child and adolescent
mental health services (CAMHS), not only directly im-
pacts the health of the patients and their families, but
also can be costly for the society as a whole [14–16].
Misdiagnosed or untreated mental health problems in
childhood and adolescence can develop into lifelong
mental health disorders requiring long-term care ser-
vices. Across the European Union, the annual accumu-
lated cost of providing mental health care for children
and adolescents is estimated to be nearly €21 billion
[16]. Undiagnosed or untreated disorders are also detri-
mental to the society’s future job market and economic
stability, with more frequent work absences and lower
productivity among individuals struggling with long-
term mental illness [17].
Every year, roughly 5% of the child and adolescent
population in Norway require specialist care from
CAMHS [18, 19]. Among Norwegian twelve-year-olds
alone, an estimated 3.4% have ADHD at any point in
time; it is one of the most common reasons for referral
to CAMHS [18]. If left untreated, ADHD can predispose
children and adolescents to psychiatric and social path-
ology later in life [20, 21]. While Norway ensures every
citizen to timely care by law [22], it is essential to optimize
the quality of diagnostics and early intervention care for
all children and adolescents displaying signs of mental ill-
ness. One modern approach to CAMHS quality assurance,
that has the potential to be cost efficient and sustainable
for long-term needs, is the incorporation of information
and communication technologies (ICT), including clinical
decision support systems (CDSSs) [23, 24].
A CDSS is a computerized system that offers guidance
to clinicians in real-time while they provide clinical care
by using existing, evidence based resources [25–27]. A
CDSS uses compiled evidence-based resources to pro-
vide clinicians with clinically relevant guidance and rec-
ommendations to help best meet the needs of each
individual patient. CDSSs are not designed to replace cli-
nicians. The architecture of a CDSS typically has three
distinct components– a Clinical Knowledge Base (do-
main of expertise based on clinical guidelines and/or
health datasets), a Reasoning Engine (cloud based
organization of evidence relative to the patient’s elec-
tronic health record (EHR)), and a User-Interface (elec-
tronic display that provides alerts and recommendations
in response to clinician’s queries) [13, 27]. CDSS model
designs however can differ; utilizing standardized clinical
guidelines (i.e., DSM-V or ICD-11), and/or aggregated
health datasets [27]. A CDSS that uses guidelines trans-
lates the guidelines into web ontology language (OWL)
modeled computerized-guidelines as the base for clinical
guidance. CDSSs that incorporate health datasets, also
known as “data-driven” CDSSs, use algorithms and data
analytics to identify patterns of care trajectories that are
relevant to the patient being seen [28–30]. While both
approaches have relative strengths, a CDSS model that is
both guideline based and data-driven also allows the
clinician to receive evidence-based support that is cus-
tomized to each individual patient, based on extensive
evidence and previous patient cases [27–30].
While CDSS implementation in general medicine has
been found to be advantageous for the quality of services
[30, 31], there is limited evidence on the use of CDSSs
for CAMHS [32]. One reason for such limited research
is the lack of accessibility to psychiatric data, especially
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those pertaining to children and adolescents. From the
established studies on CDSSs in CAMHS however, most
have identified various limitations, including a lack of in-
tegration with the EHR, limited predictive models for
diagnosis, and inadequate inclusion of multiple disorders
[32]. Norway is in a unique position to develop and im-
plement a CDSS for CAMHS because it can potentially
avoid previously identified limitations. Over the past
decade, the Norwegian National Association of Child
and Adolescent Mental Health (N-BUP), has collected
extensive data on CAMHS and compiled unique and
rich datasets, based on advanced, multidisciplinary
EHRs. However, these datasets have yet to be optimally
utilized for subsequent care, as maintaining access re-
quires ethical clearance and completion of a local data
protection impact assessment (DPIA) and risk assess-
ment to ensure privacy and confidentiality will not be
breached.
This paper presents the study design and protocol for
the evaluation of the first CDSS for CAMHS in Norway,
the Individualized Digital Decision Assist System (IDDE
AS). IDDEAS is an innovative research project, contrib-
uting to the HELSEVEL Programme (Programme on
Health, Care and Welfare Services Research) and funded
by the Norwegian Research Council (NFR). The overall
aim of IDDEAS is to improve patient care by providing
practitioners with real-time, data-driven and evidence-
based guidance that ensures earlier and more precise
decision-making, avoids misdiagnosis and reduces ineffi-
ciency in patient care practices. The principal benefit of
the study is to examine the provision of decision support
for clinicians in real-time during clinical sessions and
improvement of clinical care.
The objectives of the IDDEAS project include:
1. Evaluate the clinical utility of IDDEAS for diagnosis
and treatment of child and adolescent mental
health disorders
2. Measure clinicians’ perceived clinical usability and
appropriateness of IDDEAS for child and adolescent
mental health care
3. Measure the clinical relevance and validity of IDDE
AS’ user-interface content for clinical care
4. Implement IDDEAS in local Norwegian CAMHS
and establish recommendations for future CDSS
design and implementation for child and adolescent
mental health disorders
Methods
Study design and process
The IDDEAS project is an experimental, mixed-methods
evaluation study, within CAMHS in Norway. The study
evaluates the IDDEAS CDSS model (see Fig. 1) for diag-
nosis and treatment in CAMHS in Norway; IDDEAS will
use ADHD as the first clinical model paradigm. The
study consists of the following four stages:
Fig. 1 The IDDEAS Clinical Decision Support System Model
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Stage 1: The Assessment of Needs & Preparation of
IDDEAS.
Stage 2: The Development of the IDDEAS CDSS Model.
Stage 3: The Evaluation of the IDDEAS CDSS.
Stage 4: Implementation & Dissemination.
Stage 1: assessment of needs and preparation of IDDEAS
The preparation of IDDEAS includes the establishment
of the IDDEAS Consortium, completion of a stakeholder
analysis, clinical guidelines and clinical case vignettes
validation, and the user-interface design and modeling.
The IDDEAS Consortium consists of local CAMHS cli-
nicians, international CAMHS experts, CDSS and soft-
ware experts, as well as representatives from various
service-user organizations (i.e., ADHD Norge, Bikuben,
The National Association for Relatives in Mental
Health- LPP Tromsø, etc.).
IDDEAS stakeholder validation of clinical guidelines and
case vignettes
IDDEAS Consortium will first hold a discussion of the
current status of CAMHS in Norway and validate the
standardized clinical practice guidelines for inclusion
within the IDDEAS CDSS, as well as the clinical case vi-
gnettes to be used to evaluate the IDDEAS CDSS model.
The IDDEAS Consortium will employ clinicians and
CAMHS experts as external collaborators for the valid-
ation processes. The fictional clinical case vignettes will
be created by the IDDEAS Consortium and will be con-
sidered valid fictional representations of patient cases
with majority consensus (n = 10). Both, the guidelines
and the clinical case vignettes will be discussed and vali-
dated in collaborative focus group discussions held at
the Regional Center for Child and Youth Mental Health
and Child Welfare (RKBU), Central Norway in Trond-
heim, Norway. The clinicians in attendance will not par-
ticipate in the evaluation of IDDEAS to avoid exposure
bias and will receive compensation for their time.
IDDEAS user-Interface design
As the final part of the IDDEAS preparation, the IDDE
AS IT team will collaborate with the Consortium’s clini-
cians (i.e., local and international CAMHS experts) to
design the IDDEAS CDSS user-interface. The IDDEAS
IT team will conduct focus groups with the CAMHS ex-
perts in order to identify what is most important to ad-
dress with the design of the user-interface to ensure
sufficient usability and acceptability. The IDDEAS CDSS
user-interface will be integrated within the patient’s EHR
to display prompts and alerts for clinicians in real time.
Stage 2: development of the IDDEAS CDSS model
Following the validation of the clinical guidelines and
clinical case vignettes, and the development of the IDDE
AS user-interface design in Part 1, the model of the sys-
tem will be developed. The previously collected health
datasets (i.e., BUP-data) to be included in the Clinical
Knowledge Base will be aggregated and de-identified.
The IDDEAS research team will follow all formal data
protection procedures, including the completion of the
local DPIA and risk assessment (i.e. ROS Analysis). The
datasets will be de-identified using a list of personal
identifiers (PID) data placeholders established by the
local IDDEAS research team. Prior to integration of the
de-identified data within the model, the IDDEAS IT
team will internally test the reliability and functionality
of the PID placeholders for adequate de-identification of
the health datasets.
As the last step in the IDDEAS CDSS development
process, prior to the evaluation of the IDDEAS CDSS
model, the functionality of the Reasoning Engine will be
tested. The IDDEAS Consortium will collaboratively cre-
ate a list of clinical competence questions (CCQs) based
on a previously validated fictional patient case. The
CCQs will be input into the user-interface to simulate a
clinician querying the system during a clinical session.
The utility of the Reasoning Engine will be assessed
based on whether the system optimally receives the
CCQs, and returns a set of evidence-based, ranked, rec-
ommendations for diagnosis and treatment.
Stage 3: evaluation of the IDDEAS CDSS model
Recruitment and eligibility
Study participants are child and adolescent psychiatrists
and psychologists (n = 30). Participants will represent
four child and adolescent mental health clinics (BUP-
clinics); the clinics will be chosen at random in collabor-
ation with the N-BUP (Norwegian Association for Child
and Adolescent Psychiatry) representative. Purposive
sampling will be undertaken to ensure there is a balance
among participants, in regards to gender, location in the
country, expertise and socioeconomic status. This ap-
proach to sampling will limit bias and ensure inclusion
of varied perspectives. Recruitment of participants for
enrollment in the study will begin no earlier than August
2020. Participants are deemed eligible if they are cur-
rently practicing as a child and adolescent psychologist
or psychiatrist in Norway.
Sample size
The sample size was calculated based on the optimal
power value in order to ensure the size of the sample is
appropriate for this study. There is the assumption that
the effect of decision support is to increase specificity
from 0.50 to 0.80 and only moderately change sensitivity.
With the assumption that the effect of decision support
is to increase specificity from 0.50 to 0.80 and only mod-
erately change sensitivity, the sample size (n = 30) can be
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calculated with an effect size of at least 1.0 and desired
power value of .80 (80%); the assumption of the specifi-
city increase, to detect the statistical significance (p <
0.05) on a dichotomous variable with 80% power, the
number of subjects required is 30.
Procedure
The evaluation of the CDSS model initially will entail as-
sessments of how child and adolescent psychologists and
psychiatrists perceive the usability, acceptability, validity,
and relevance of the CDSS model for use in their clinical
practice. The evaluation of the CDSS model will take
place in two phases, as follows: Phase 1. Vignette-Based
Evaluation and Phase 2. Live Patient Evaluation. Both
phases of the CDSS evaluation will occur in randomly
selected CAMHS clinics. The incremental evaluation
phases will take place within the trial period of August
2020–2023. Using a pre-post design, for both phases of
the evaluation, participants will compare the provision
of clinical care with use of the CDSS, to the daily clinical
practice, as the control. Prior to participation in the
evaluation written consent will be obtained from all par-
ticipants by the project leader. Participants will be in-
formed their participation is voluntary and they can
withdraw from the study at any time without penalty.
Phase 1: vignette-based evaluation After completion
of informed consent procedures, including assessments
of conflicts of interest, clinicians will be asked to
complete a brief demographic questionnaire. They will
then be provided the educational manual on how to
navigate the IDDEAS system. Clinicians will then be
asked to critically appraise ten previously validated clin-
ical case vignettes (i.e., fictional patient cases that have
been “referred” for assessment of ADHD). Clinicians will
first appraise five of the cases without the use of the sys-
tem and five using the CDSS. The cases will be ran-
domly allocated by the PhD student with the project and
verified by the project leader. The allocation sequence
will be computer generated.
Phase 2: live patient evaluation Phase 2 will entail a
live patient evaluation study of the IDDEAS CDSS
model for the diagnosis and treatment of ADHD among
children and adolescents in which seven standardized
patient-encounter videos will be assessed with and with-
out the use of the IDDEAS system. The aim of this
phase of the study is to determine whether IDDEAS in
its entirety can: meet the desired requirements; can yield
an output that meets specifications with acceptable
capability.
Data collection
Qualitative methods All participants will be surveyed
using both qualitative and quantitative methods. In the
vignette-based evaluation, all participants will be asked to
complete a “cognitive- walkthrough” in which they will
think-aloud through the entire process of critically apprais-
ing each clinical vignette case. In the live patient evaluation,
the same procedure will be conducted to evaluate clinical
care with the CDSS, based on seven standard patient en-
counter videos. All participants will be queried with a semi-
structured interview in order to gain understanding of the
participants’ overall experience, challenges encountered,
strengths, and any other aspects of the system requiring ad-
justment. The semi-structure interviews will be held dir-
ectly after the completion of the case vignettes. For both
phases of the evaluation, the cognitive-walkthrough and
semi-structured interview will be audio recorded and tran-
scribed. Transcripts will be transferred to NViVo 10 soft-
ware for coding and data analysis [33, 34].
Quantitative methods All quantitative measurements
will be translated from English to Norwegian as needed
and compiled into an assessment package in accordance
with the WHO’s guideline “Process of Translation and
Adaptation of Instruments” (see Table 1) [35]. Data will
also be collected on the sensitivity, specificity, and rele-
vance of the IDDEAS system. Data will be collected on
standardized score sheets, transferred to a Microsoft
Table 1 Quantitative Assessment Measurements
Full Name Abbreviation About Measure
System Usability
Scale
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Excel spreadsheet, and retained/stored in a database sys-
tem serving as a scalable informatics framework (i.e., In-
formatics for Integrating Biology & the Bedside (i2b2))
for subsequent analysis. The database system will pro-
vide an ontology-based flexibility that enables aggrega-
tion of multiple datasets, as well as easy extraction of
individual clinical cases. All participants’ demographic
information will also be anonymized with a randomly
assigned unique study ID, aggregated and encrypted prior
to transfer to a secure data repository for storage. Access
to participants’ demographic information and study IDs
will only be available to the IDDEAS project leader and
the PhD student affiliated with the project. Datasets will
be stored in a secure data repository at the Regional Cen-
ter for Child and Youth Mental Health and Child Welfare
(RKBU), Department of Mental Health, Norwegian Uni-
versity of Science and Technology (NTNU).
Data analysis
Qualitative methods For both phases of the evaluation,
the semi-structured interviews and the “cognitive- walk-
through” recordings, will both be analyzed using thematic
(i.e., Grounded Theory) and content analysis. The the-
matic analysis will identify patterns within the partici-
pants’ transcribed response to identify attributes of the
overall appropriateness, including: challenges experienced
assessing the cases, limitations in the interactive compo-
nent of the system, strengths of the system’s design, and
potential additions to the system’s design in order to im-
prove the experience. Content analysis will be used to as-
sess the frequency of items and prompts used during the
interviews [33, 36, 37].
Quantitative methods The Likert scale items will be
assessed based on inter-rater reliability in accordance with
pre-specified and previously validated criteria. The usabil-
ity, content validity, and user engagement data will be
compiled and analyzed with statistical analysis software
(SPSS software platform) to determine whether the cri-
teria are met for each measurement (i.e., SUS ≥ 70; UES ≥
70; CVI > 0.80) [38]. The criteria will be analyzed by com-
puting the average of the rating scores proposed by partic-
ipants for each Likert item and finding the degree of inter-
rater agreement on the IDDEAS system attributes (i.e.,
prompt/alert provided in system user-interface).
The sensitivity, specificity, and relevance of the IDDEAS
system for ADHD diagnosis and treatment will also be
assessed based on overall percentage of agreement among
participants on appropriate diagnosis, as well as the pro-
posed biopsychosocial treatment plan. A mixed model lo-
gistic regression will be used with correct diagnosis as the
dependent variable, decision support (yes or no) and pa-
tient status (ADHD or non-ADHD) as fixed effects.
IDDEAS CDSS system modification and refinement
Between the two phases of the IDDEAS evaluation
study, adjustments to the measurement tools and the
system will be made. Based on the results of the
vignette-based evaluation, prior to the live patient evalu-
ation, adjustments to the questionnaires, the CDSS con-
tent provided for practitioners, and the overall design of
the user-interface will be adjusted as necessary.
Outcomes
The primary outcome of the study will be the clinical
utility of the IDDEAS CDSS for diagnosis and treatment
of child and adolescent mental health disorders. The pri-
mary outcome will be measured by reviewing partici-
pants’ clinical diagnosis and treatment plans as a
measure of sensitivity and specificity when using the
CDSS compared to when not using the CDSS, upon
completion of both phases of the evaluation.
The secondary outcomes of the study will be subject-
ive measures. The three secondary outcome measures
are perceived clinical usability, perceived clinical rele-
vance and validity, as well as perceived appropriateness
of the IDDEAS CDSS. The perceived clinical usability of
the CDSS will be measured using the system usability
scale (SUS) [33, 39, 40]. The perceived appropriateness
of the CDSS will be measured using the user-
engagement scale (UES) [41–43]. The perceived clinical
relevance and validity of the system’s user-interface will
be measured using the content validity index (CVI) [44].
All outcomes will be measured directly following both
phases of the evaluation of the IDDEAS CDSS (i.e.,
within 24 h).
Stage 4: Implementation & Dissemination
From the outset of the IDDEAS project, a scientific
communication and dissemination plan will be imple-
mented in line with both the Golden Road and the
Green Road for dissemination. Findings and relevant
study information will be regularly disseminated to
the academic community, healthcare professionals,
service-user organizations and the general public at
conferences, congresses, workshops, and through
social-media platforms (i.e., Twitter, Facebook, Insta-
gram, etc.). Scientific communication will be dissemi-
nated as peer-reviewed publications in both national
and international journals annually. Practical informa-
tion on the IDDEAS CDSS will also be made available
for all end-users, including an informative website,
online tutorial and user guides. Prior to implementa-
tion of IDDEAS, preselected Consortium members
and clinical experts will guide trial participants
through training courses in order to qualify the clini-
cians as trainers for future IDDEAS End-User training
courses. Follow-Up reviews and support meetings will
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be held to receive the clinicians’ feedback on using
the IDDEAS CDSS. IDDEAS CDSS workshops will be
held at the Norwegian CAMHS annual congress (i.e.,
N-BUP Kongressen).
Discussion
IDDEAS will utilize qualitative and quantitative methods
to determine whether the implementation of a clinical
guideline and data-driven CDSS model in CAMHS will
improve the quality of diagnoses and treatment of child
and adolescent mental health disorders. The inclusion of
two phases of evaluation within the IDDEAS trial will
allow for a thorough assessment of the specific aspects
of the CDSS that are suitable and those that need to be
addressed for improvement of clinical care based on cli-
nician’s subjective perception, as well as objective statis-
tical analysis.
IDDEAS’ expected impacts include, but are not limited
to, improved use of available health data, integration of
predictive interventions in care, better management of
complex clinical situations in child and adolescent men-
tal health, enhanced collaboration among stakeholders
involved in patient care, and amplified inter-service co-
ordination in management of patient’s health. Further-
more, IDDEAS will help to improve patients’
understanding of the clinical decision- making involved
in their treatment, as well as help ensure greater partici-
pation and improved transparency for the patients’ fam-
ilies. Overall IDDEAS will improve the quality of mental
health care for children and adolescents by using in-
novative data-analytics within the CDSS model to pro-
vide support to clinicians that is evidence-based and
customized to meet the needs of each individual patient.
With quality improvement of clinical standards and en-
hanced precision of care, IDDEAS will also improve the
efficiency of practices, allowing for more patients to be
seen and receive a diagnosis in a timely-manner.
Our research will provide a comprehensive under-
standing of how to approach the use of a CDSS as a
novel innovation for CAMHS. All limitations and chal-
lenges faced through the processes of designing, model-
ling, evaluating and testing the implemented IDDEAS
CDSS model, can serve as valuable learning opportun-
ities for future CDSS implementations in CAMHS.
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